Startup profile · funding coverage
Mentari Therapeutics funding, valuation and investors
Biotech developing anti-PACAP and anti-CGRP bispecific antibodies for migraine prevention.
Keep track of Mentari Therapeutics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Private placement
~$290M · 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$200M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth
Overview
Mentari Therapeutics is a clinical-stage biotech developing bispecific antibodies for migraine prevention, including MT-001 (anti-PACAP) and MT-002 (anti-CGRP). Spun out from Paragon Biosciences, Mentari raised approximately $290M in a 2026 private placement led by Fairmount Funds with Andreessen Horowitz Bio + Health participating, ahead of a planned reverse merger with InMed Pharmaceuticals. A follow-on $200M placement in July 2026 included Fairmount, Venrock Healthcare, and Blackstone Multi-Asset.
Why Mentari Therapeutics is interesting
Paragon spinout targeting dual migraine pathways — a16z Bio + Health backed ~$290M private placement (2026) ahead of reverse merger with InMed, betting bispecifics beat single-pathway CGRP drugs.
Product & use cases
Mentari develops bispecific biologics targeting both PACAP and CGRP pathways implicated in migraine — aiming for efficacy in patients who incompletely respond to existing anti-CGRP monoclonal antibodies like Aimovig or Emgality.
- Preventive migraine treatment for patients failing single-pathway CGRP therapies
- Dual-mechanism biologics addressing PACAP and CGRP biology simultaneously
- Clinical development toward BLA filing via InMed merger vehicle
Key facts
- Private placement (2026): ~$290M led by Fairmount; a16z Bio + Health participated (BioPharma Dive)
- Follow-on (Jul 2026): $200M from Fairmount, Venrock Healthcare, Blackstone Multi-Asset
- Programs MT-001 (anti-PACAP) and MT-002 (anti-CGRP)
- Planned reverse merger with InMed Pharmaceuticals
Funding history (newest first)
Private placement
2026 ~$290M- Fairmount Funds (lead)
- Andreessen Horowitz (participant)
Source: https://www.biopharmadive.com/news/mentari-therapeutics-migraine-private-placement/
Follow-on placement
2026-07 $200M- Fairmount Funds (participant)
- Venrock Healthcare (participant)
Investors in our directory
Funds linked from Mentari Therapeutics's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Dual-pathway bispecific approach differentiates from crowded anti-CGRP field — a16z Bio + Health participation in $290M+ placements signals conviction in next-gen migraine biology.
Migraine biologics is a multi-billion market dominated by anti-CGRP mAbs. Mentari's bispecific thesis must show clear superiority in non-responders to justify premium pricing and payer coverage.
-
Amgen (Aimovig) incumbent
First anti-CGRP migraine prevention; established formulary position Mentari must displace.
-
Biohaven / Pfizer (Nurtec) incumbent
CGRP-targeting acute and preventive options; single-pathway vs Mentari bispecific.
-
Lundbeck (Vyepti) incumbent
IV CGRP preventive; Mentari bets dual targeting improves outcomes.
Notable stories
- Mentari spun from Paragon Biosciences' incubator model — applying Paragon's rare-disease and biologics expertise to the large migraine market with novel bispecific approach.
- The InMed reverse merger structure gives Mentari a public vehicle for clinical milestones without traditional IPO timing constraints.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Mentari Therapeutics's financing or category context.
FAQs about Mentari Therapeutics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.